Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1Gastrointestinal 1

Conditions

Melanoma 32Neoplasms 14Carcinoma, Non-Small-Cell Lung 10Colorectal Neoplasms 8Ovarian Neoplasms 7Multiple Myeloma 6Breast Neoplasms 6Pancreatic Neoplasms 5Neoplasm Metastasis 4Hematologic Neoplasms 4Solid Tumors 3Neoplasms by Site 3Lymphoma, Non-Hodgkin 3Lung Neoplasms 3Leukemia, Myeloid, Acute 3Gastrointestinal Neoplasms 3Cholangiocarcinoma 3Brain Neoplasms 3Urinary Bladder Neoplasms 2Thyroid Neoplasms 2Thyroid Carcinoma, Anaplastic 2Thyroid Cancer, Papillary 2Solid Tumor 2Skin Neoplasms 2Sarcoma 2Prostatic Neoplasms 2Neoplasms by Histologic Type 2Leukemia, Myelomonocytic, Chronic 2Gallbladder Neoplasms 2Fallopian Tube Neoplasms 2

Interventions

Gemcitabine 92Cisplatin 70Oxaliplatin 37Capecitabine 37durvalumab 29Fluorouracil 26pembrolizumab 24Leucovorin 22S 1 (combination) 18Nivolumab 13Irinotecan 13Bevacizumab 13lenvatinib 12tremelimumab 10apatinib 8Trastuzumab 7Injections 7Albumin-Bound Paclitaxel 7130-nm albumin-bound paclitaxel 7Paclitaxel 6Immune Checkpoint Inhibitors 6Docetaxel 6titanium silicide 5surufatinib 5envafolimab 5camrelizumab 5atezolizumab 5Folfox protocol 5Drug Therapy 5Carboplatin 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Biliary Tract Neoplasms × cobimetinib × Clear all
NCT02091141 2024-07-23

My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors

Genentech, Inc.

Phase 2 Completed
673 enrolled 22 charts
GastrointestinalGenitourinary

Biliary Tract Neoplasms, Urinary Bladder Neoplasms, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡